Norges Bank Ascendis Pharma A/S Transaction History

Norges Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$69.96 - $97.84 $260,740 - $364,649	-3,727 Closed	0 $0
Q2 2022 Aug 14, 2023	BUY	$78.08 - $117.61 $291,004 - $438,332	3,727 New	3,727 $346,000
Q1 2022 May 12, 2023	BUY	$102.18 - $135.75 $380,824 - $505,940	3,727 New	3,727 $437,000
Q1 2022 May 09, 2022	SELL	$102.18 - $135.75 $3.96 Million - $5.26 Million	-38,771 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$127.1 - $169.66 $4.93 Million - $6.58 Million	38,771 New	38,771 $5.22 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.